Introduction {#s1}
============

Long noncoding RNAs (lncRNAs) have emerged as regulators of diverse biological processes. Among these transcripts, *Noncoding RNA activated by DNA damage* (*NORAD*) is particularly noteworthy, due to its unusually abundant expression in mammalian cells and tissues and strong evolutionary conservation across mammalian species. Initial studies of *NORAD* revealed that this lncRNA is required to maintain genomic stability in mammalian cells ([@bib4]), and provided strong evidence that this function is mediated through the ability of *NORAD* to bind to and negatively regulate PUMILIO RNA binding proteins (PUM1 and PUM2) in the cytoplasm ([@bib4]; [@bib11]). PUM proteins bind with high specificity to the eight nucleotide (nt) PUMILIO response element (PRE) (UGUANAUA or UGUANAUN) on target messenger RNAs (mRNAs), triggering their deadenylation, decapping, and eventual degradation ([@bib5]; [@bib8]). Notably, *NORAD* contains 18 conserved PREs and has the capacity to bind a large fraction of PUM1/2 within the cell, although it is not yet known whether *NORAD* limits PUM activity through a simple sequestration model or whether additional mechanisms contribute to PUM inhibition. Regardless, loss of *NORAD* results in PUM hyperactivity and increased repression of PUM targets that include important regulators of mitosis, DNA repair, and DNA replication, resulting in a dramatic genomic instability phenotype in *NORAD*-deficient cells and mouse tissues ([@bib3]; [@bib4]). Accordingly, PUM1/2 overexpression is sufficient to phenocopy loss of *NORAD* in both human cells and mice ([@bib3]; [@bib4]), while PUM1/2 loss-of-function suppresses the genomic instability phenotype in *NORAD* knockout cells ([@bib4]).

Recently, an alternative mechanism for the regulation of genomic stability by *NORAD* was proposed ([@bib7]). Proteomic analysis of the *NORAD* interactome revealed an interaction with RBMX, an RNA binding protein that contributes to the DNA damage response ([@bib1]). Subsequent experiments suggested that the *NORAD*:RBMX interaction facilitates the assembly of a ribonucleoprotein (RNP) complex in the nucleus that includes Topoisomerase I (TOP1) and other proteins that are critical for genome maintenance. Importantly, PUM and RBMX interact with different sites on *NORAD* and function in distinct subcellular compartments. Thus, while it remains to be determined whether the *NORAD*:RBMX interaction is necessary for regulation of genomic stability, both PUM and RBMX may play important, non-mutually exclusive roles in the genome maintenance functions of *NORAD*.

Here, we further examined the mechanism by which *NORAD* functions to maintain genome stability in human cells and directly tested the requirement for PUM and RBMX interactions in this activity. RNA fluorescent in situ hybridization (FISH) using a panel of probes spanning the entire length of *NORAD*, as well as cellular fractionation studies, definitively demonstrated that this lncRNA localizes predominantly to the cytoplasm and does not detectably redistribute to the nucleus upon induction of DNA damage. Genetic rescue experiments in *NORAD* knockdown cells established that PUM binding is essential for maintenance of genomic stability whereas interaction with RBMX is completely dispensable for this function. Further experiments demonstrated that RBMX is not required for induction of *NORAD* following DNA damage nor its cytoplasmic localization. Together, these studies establish the importance of the *NORAD*:PUM axis in regulating genomic stability in mammalian cells and provide a foundation for further dissection of the mechanism and physiologic role of this pathway.

Results and discussion {#s2}
======================

*NORAD* localizes predominantly to the cytoplasm with or without DNA damage {#s2-1}
---------------------------------------------------------------------------

Initial studies of *NORAD* reported a predominantly cytoplasmic localization of this lncRNA in human cell lines, based on RNA FISH using pools of fluorescently-labeled oligonucleotide probes and subcellular fractionation experiments ([@bib4]; [@bib11]). Recently, however, a distinct localization pattern was reported based upon RNA FISH performed using a commercially-available kit with a proprietary set of oligonucleotide probes that hybridize to an unknown segment of *NORAD* ([@bib7]). In these more recent experiments, *NORAD* was reported to localize equally between the nucleus and cytoplasm and appeared to redistribute almost entirely to the nuclear compartment upon treatment of cells with the DNA damaging agents camptothecin and doxorubicin. Importantly, a single cell line (human colon cancer cell line HCT116) was used in both the previous ([@bib4]) and more recent studies ([@bib7]), arguing against a cell-type specific difference in *NORAD* trafficking as the cause of these discordant results.

We considered the possibility that the disparate observed localization patterns could be due to unrecognized processing of the *NORAD* transcript, such that different segments of the RNA that are recognized by the different FISH probes accumulate in distinct subcellular compartments. To investigate this possibility, and to reliably establish the localization of the entire *NORAD* transcript, we generated a panel of 11 in vitro transcribed RNA FISH probes spanning the complete *NORAD* sequence ([Figure 1A](#fig1){ref-type="fig"}) ([@bib6]). One probe, that recognized a segment of *NORAD* containing an Alu repeat element (probe 7), gave rise to a nonspecific nuclear signal that was present in both *NORAD*^+/+^ and *NORAD^--/--^* HCT116 cells. The remaining 10 probes produced a highly consistent, predominantly cytoplasmic, punctate localization pattern in wild-type cells that was absent in *NORAD^--/--^* cells ([Figure 1A--B](#fig1){ref-type="fig"}). These results were confirmed using subcellular fractionation followed by quantitative reverse transcriptase-PCR (qRT-PCR) using primers located at the 3′ or 5′ ends of *NORAD*, which revealed that 80--90% of the transcript is localized to the cytoplasmic compartment ([Figure 1C](#fig1){ref-type="fig"}).

![*NORAD* localizes predominantly to the cytoplasm.\
(**A**) RNA FISH in HCT116 cells using a panel of 11 probes tiling the entire *NORAD* transcript reveals a predominantly cytoplasmic signal that is absent in *NORAD^--/--^* cells with all probes except probe 7, which produces a nonspecific signal likely due to the presence of an Alu repeat element. *NORAD* FISH signal in red, DAPI counterstain in blue. Locations of PREs indicated by arrowheads. ND1-ND5 represent repetitive *NORAD* domains, as previously described ([@bib4]). (**B**) RNA FISH image using probe 3 showing a wider field of cells. (**C**) Subcellular fractionation followed by qRT-PCR in HCT116 cells using primers located at the 3′ or 5′ end of *NORAD*, in *GAPDH* (cytoplasmic control), or in *NEAT1* (nuclear control). n = 3 biological replicates each with three technical replicates.](elife-48625-fig1){#fig1}

Next, we examined *NORAD* localization following treatment of cells with agents that induce DNA damage ([Figure 2---figure supplement 1A--B](#fig2s1){ref-type="fig"}). RNA FISH using the panel of probes spanning *NORAD* revealed clear cytoplasmic localization after treatment with doxorubicin or camptothecin, without a significant increase in nuclear signal compared to untreated cells ([Figure 2A--B](#fig2){ref-type="fig"}). Consistent with the previously reported induction of *NORAD* after DNA damage ([@bib4]), a clear increase in cytoplasmic *NORAD* signal was apparent in treated cells ([Figure 2B](#fig2){ref-type="fig"}). These findings were further corroborated by subcellular fractionation experiments following treatment with DNA damaging agents, which confirmed that *NORAD* remained predominantly in the cytoplasmic compartment at all time points ([Figure 2C](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1C](#fig2s1){ref-type="fig"}). Interestingly, we observed a modest increase in nuclear *NORAD* levels that peaked after 12 hr of camptothecin or doxorubicin treatment. We speculated that this might represent a burst of *NORAD* transcription in response to accumulating DNA damage. To test this hypothesis, we co-treated cells with DNA damaging agents and the transcriptional inhibitor actinomycin D. As expected, this completely abrogated any detectable increase in nuclear *NORAD* abundance in treated cells ([Figure 2D](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1D](#fig2s1){ref-type="fig"}).

![*NORAD* remains predominantly in the cytoplasm after treatment with DNA damaging agents.\
(**A**) RNA FISH in HCT116 cells using the indicated *NORAD* probes following a 12 hr treatment with doxorubicin or camptothecin. (**B**) *NORAD* RNA FISH (probe 5) after the indicated drug treatments. Images captured with identical microscope settings. (**C--D**) Subcellular fractionation followed by qRT-PCR in HCT116 cells after treatment with camptothecin (**C**) or camptothecin plus actinomycin D (**D**) for the indicated number of hours. n = 3 biological replicates each with three technical replicates. ns, not significant; \*p\<0.05; \*\*p\<0.01; \*\*\*p\<0.001; one-tailed t-test comparing each sample to the 0 hr time-point.](elife-48625-fig2){#fig2}

These comprehensive RNA FISH and subcellular fractionation experiments provide definitive evidence that *NORAD* is a predominantly cytoplasmic RNA in HCT116 cells and does not detectably redistribute to the nucleus upon DNA damage. These findings are consistent with the reported localization of *NORAD* in other human and mouse cell lines ([@bib3]; [@bib4]; [@bib11]). We speculate that the disparate localization pattern observed using a commercially-available RNA FISH probe set ([@bib7]) most likely represented a non-specific signal.

PUM1, PUM2, and RBMX are components of the *NORAD* interactome {#s2-2}
--------------------------------------------------------------

Previous crosslinking-immunoprecipitation coupled with high throughput sequencing (CLIP-seq) studies demonstrated that *NORAD* is the preferred binding partner of PUM2 in both human cells ([@bib4]) and mouse brain ([@bib3]). In light of these findings, it was surprising that PUM1/2 were not reported among the most enriched *NORAD*-bound proteins in the recent RNA antisense purification with quantitative mass spectrometry (RAP-MS) experiments performed in HCT116 cells that identified the *NORAD*:RBMX interaction ([@bib7]). Since these RAP-MS experiments utilized pulse labeling with 4-thiouridine to crosslink *NORAD* to protein interactors, a bias towards detection of proteins that bind to newly synthesized *NORAD* would be expected, potentially explaining the enrichment of nuclear interactors observed. Nevertheless, we reanalyzed the published RAP-MS dataset to determine whether PUM1 or PUM2 were enriched in *NORAD* pull-downs compared to control *RMRP* pull-downs. Peptides were identified and scored using a combined algorithm that employed three search engines (Sequest HT, Mascot, and MS Amanda). Isoforms of PUM1 and PUM2, along with RBMX, were indeed identified as significantly-enriched interacting partners of *NORAD* compared to *RMRP* ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). Notably, PUM1 was more enriched than PUM2 in our analysis, which may reflect its higher abundance in HCT116 cells ([@bib4]). These results confirmed that both PUM proteins and RBMX are identified by RAP-MS as significant *NORAD*-interacting partners.

Binding of PUMILIO, but not RBMX, to *NORAD* is necessary for genome stability {#s2-3}
------------------------------------------------------------------------------

Genetic epistasis experiments have strongly implicated a role for PUM1/2 in the regulation of genomic stability by *NORAD*, with PUM2 overexpression phenocopying, and PUM1/2 knockdown suppressing, the effects of *NORAD* deletion ([@bib3]; [@bib4]). Nevertheless, it has not yet been directly tested whether binding of PUM1/2 is required for *NORAD* function. Similarly, a requirement for RBMX binding in genome maintenance by *NORAD* has not been established. Therefore, to directly interrogate the importance of PUM and RBMX binding for *NORAD* function, we generated a series of mutant *NORAD* constructs lacking either PUM or RBMX binding sites ([Figure 3A](#fig3){ref-type="fig"}). For each of the 18 PREs within *NORAD*, the UGU sequence, which is essential for PUM binding ([@bib2]; [@bib12]), was mutated to ACA to abolish PUM interaction (PREmut construct). To remove the RBMX binding site, the first 898 nucleotides (nt) of *NORAD* were deleted ([@bib7]) (5′ deletion construct). We also sought to determine whether PUM or RBMX binding regions of *NORAD* could represent minimal functional domains that are sufficient for maintaining genomic stability. To this end, we generated a fragment comprising *NORAD* domain 4 (ND4), which represents the most conserved of five repeated segments within this lncRNA termed *NORAD* domains ([@bib4]) and contains 4 PREs (nt 2494--3156). An RBMX binding site fragment, representing the 5′ end of *NORAD* (nt 33--898), which also harbors one PRE, was also generated (5′ fragment).

![Generation and stable expression of *NORAD* constructs.\
(**A**) Schematic depicting wild-type or mutant *NORAD* constructs. *NORAD* sequence conservation in mammals (UCSC Genome Browser Hg38 PhastCons track) highlights the strong conservation of the region of *NORAD* harboring PREs (arrowheads). PREmut contains 18 UGU to ACA mutations in PREs (gray arrowheads); 5′ deletion (5′ del) lacks the RBMX binding site (nt 1--898) ([@bib7]); 5′ fragment (5′ frag) spans the RBMX binding site (nt 33--898); ND4 construct represents the most conserved segment of *NORAD* (nt 2494--3156). (**B**) Schematic depicting insertion of constructs into the *AAVS1/PPP1R12C* locus using TALENs. (**C**) qRT-PCR analysis of expression of each *NORAD* construct in HCT116 CRISPRi cells after infection with control or endogenous *NORAD*-targeting sgRNAs. Expression was normalized to endogenous *NORAD* level, represented by expression in *AAVS1*-GFP cells infected with sgControl (replicate 1 samples normalized to sgControl *AAVS1*-GFP replicate 1; replicate 2 samples normalized to sgControl *AAVS1*-GFP replicate 2). The data in the left graph were generated with a primer pair in ND4 that does not amplify the 5′ fragment, while the right graph used primers at the *NORAD* 5′ end. Replicates represent two independently-derived *AAVS1* knock-in and sgRNA-infected cell lines. Values normalized to *GAPDH* expression. n = 3 technical replicates per sample.](elife-48625-fig3){#fig3}

Wild-type or mutant *NORAD* constructs, as well as a control GFP sequence, under the control of a constitutive promoter were introduced into the *AAVS1/PPP1R12C* locus of HCT116 cells using a previously published TALEN pair ([@bib9]) ([Figure 3B](#fig3){ref-type="fig"}). Endogenous *NORAD* was then depleted using CRISPR interference (CRISPRi) with a single-guide RNA (sgRNA) targeting the endogenous *NORAD* promoter. As expected, in cells infected with a non-targeting control sgRNA (sgControl), increased total levels of *NORAD* were observed upon expression of *NORAD* rescue constructs in trans (\~1.5--6 fold overexpression, depending on the construct) ([Figure 3C](#fig3){ref-type="fig"}). Upon silencing of the endogenous *NORAD* locus, however, near physiologic expression levels for all constructs were achieved, with the exception of the 5′ fragment which exhibited \~3 fold overexpression, perhaps indicating increased stability of this transcript segment when expressed in isolation.

We next used UV crosslinking and RNA immunoprecipitation (RIP) to assess binding of wild-type and mutant *NORAD* transcripts to endogenous PUM1, PUM2, and RBMX. Pull-downs of each of these proteins resulted in the expected enrichment of wild-type *NORAD*, but not *GAPDH*, relative to immunoprecipitation with control IgG ([Figure 4A](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). The PREmut transcript as well as the 5′ fragment did not bind to PUM1/2 but were recovered in RBMX RIP samples as efficiently as wild-type *NORAD*. In contrast, the 5′ deletion construct and ND4 fragment retained PUM1 and PUM2 binding activity, but interaction with RBMX was not detectable above background. Furthermore, RNA FISH documented a predominantly cytoplasmic localization pattern of each construct ([Figure 4B](#fig4){ref-type="fig"}).

![RNA immunoprecipitation and localization of *NORAD* constructs.\
(**A**) UV crosslinking and RNA immunoprecipitation (RIP) was used to assess PUM1, PUM2, and RBMX interactions with GFP mRNA or the indicated *NORAD* constructs. After knock-in of the indicated constructs to the *AAVS1* locus in HCT116 CRISPRi cells, endogenous *NORAD* was silenced with a lentivirally-expressed sgRNA. qRT-PCR was used to assess *NORAD* or *GAPDH* recovery in each RIP sample, expressed as fold-enrichment over pull-down with IgG. The data in the left graphs were generated with a primer pair in ND4 that does not amplify the 5′ fragment, while the right graphs used primers at the *NORAD* 5′ end. n = 2 biological replicates, each measured with three technical replicates. (**B**) Representative RNA FISH images of wild-type or mutant *NORAD* transcripts expressed from the *AAVS1* locus in HCT116 CRISPRi cells after knockdown of endogenous *NORAD*. Probe 10 was used for full-length *NORAD*, PREmut, and 5′ del constructs; probe 1 was used for 5′ frag; and probe 6 was used for ND4.](elife-48625-fig4){#fig4}

Genome stability was first assessed in cell populations expressing wild-type or mutant *NORAD* constructs by quantifying the number of aneuploid cells in each population using DNA FISH for marker chromosomes 7 and 20, as described previously ([@bib4]) ([Figure 5A--B](#fig5){ref-type="fig"}). Importantly, no significant increase in aneuploidy was observed in any of the *NORAD* rescue populations after infection with non-target sgRNA (sgControl), indicating that overexpression of the *NORAD* constructs in trans did not trigger genomic instability. Furthermore, as expected, knockdown of endogenous *NORAD* in GFP-control cells resulted in a significant accumulation of aneuploid cells. The frequency of aneuploidy observed under these conditions was very similar to that observed previously in *NORAD^--/--^* HCT116 cells ([@bib4]). Expression of wild-type *NORAD* in trans was sufficient to fully suppress the accumulation of aneuploid cells after silencing endogenous *NORAD*. Cells expressing the PREmut transcript, however, exhibited high levels of aneuploidy, demonstrating that loss of PUM binding abrogated the ability of *NORAD* to maintain genomic stability. Moreover, the 5′ deletion construct that lacks the RBMX binding site, but preserves the PUM interaction, was fully functional in this assay and completely prevented the accumulation of aneuploid cells. Thus, RBMX binding to *NORAD* is dispensable for genome maintenance. Remarkably, we observed a strong suppression of aneuploidy in cells expressing the minimal ND4 fragment, further supporting the centrality of the PUM interaction for *NORAD* function, while the 5′ fragment of *NORAD* had no activity in this assay.

![PUMILIO, but not RBMX, binding to *NORAD* is necessary for genome stability.\
(**A**) Representative DNA FISH images for chromosome 7 (green) and 20 (red) showing examples of cells with modal (2 n) and non-modal (2n ± 1) chromosome numbers. Arrowheads indicate chromosome gain or loss. (**B**) HCT116 CRISPRi cells stably expressing the indicated *AAVS1* knock-in construct were infected with lentivirus expressing control or endogenous *NORAD*-targeting sgRNA. Aneuploidy was assayed 18--21 days later using DNA FISH for chromosome 7 and 20, and the frequency of interphase cells exhibiting a non-modal (2 n) chromosome number was scored. Replicates represent two independently-derived *AAVS1* knock-in and sgRNA-infected cell lines. 200 nuclei were scored per sample. The dotted line denotes the highest level of background aneuploidy observed in sgControl-infected cells. ns, not significant; \*p\<0.05; \*\*p\<0.01; \*\*\*p\<0.001; \*\*\*\*p\<0.0001, chi-square test comparing sg*NORAD* to sgControl for each replicate. (**C**) Representative images of anaphase cells with normal or abnormal (arrowheads) chromosome segregation in DAPI-stained HCT116 CRISPRi cells. (**D**) The frequency of mitotic cells exhibiting chromosome segregation defects was determined in both biological replicates of each cell population (100 anaphase cells assayed per sample). The dotted line denotes the highest percentage of chromosome segregation defects observed in sgControl-infected cells. ns, not significant; \*p\<0.05; \*\*p\<0.01; \*\*\*p\<0.001; \*\*\*\*p\<0.0001, chi-square test comparing all sg*NORAD* replicate 1 samples to sgControl GFP replicate 1 and all sg*NORAD* replicate 2 samples to sgControl GFP replicate 2.](elife-48625-fig5){#fig5}

To further assess the role of RBMX and PUM binding in genome maintenance by *NORAD*, we quantified the frequency of chromosomal segregation defects in HCT116 cell populations expressing the various *NORAD* rescue constructs. We have previously demonstrated that *NORAD* knockout cells exhibit a significant increase in mitotic errors ([@bib4]) and the same phenotypic assay was later used by Munschauer et al. to confirm genomic instability in *NORAD* and *RBMX* knockdown cells ([@bib7]). Examination of DAPI-stained anaphase nuclei revealed the expected increase in chromosomal segregation defects in GFP-expressing control cells following *NORAD* knockdown ([Figure 5C--D](#fig5){ref-type="fig"}). Consistent with our analyses of aneuploidy using DNA FISH, expression of full-length *NORAD*, or the 5′ deletion construct lacking the RBMX binding site, reversed this phenotype and suppressed the increase in mitotic errors. We further documented that mutation of the PUM binding sites (PREmut) abolished *NORAD* function in this assay. Finally, we found that the ND4 segment containing several highly conserved PUM binding sites, but not the 5′ fragment encompassing the RBMX binding site, exhibited significant rescue activity in this assay. Overall, these data provide compelling evidence that PUM, but not RBMX, binding to *NORAD* is necessary for the maintenance of genomic stability by this lncRNA.

RBMX is not required for *NORAD* expression or localization {#s2-4}
-----------------------------------------------------------

Although RBMX is not required for maintenance of genomic stability by *NORAD*, we were able to confirm binding of this protein to the 5′ end of *NORAD*, as reported ([@bib7]) ([Figure 3](#fig3){ref-type="fig"} and [Figure 4A](#fig4){ref-type="fig"}). Thus, we investigated whether RBMX functions as an upstream regulator of *NORAD* expression or localization. Depletion of RBMX using CRISPRi resulted in an increase in *NORAD* expression that was further augmented by doxorubicin treatment ([Figure 6A](#fig6){ref-type="fig"}). We speculate that this increase in *NORAD* levels may be an indirect effect of the previously reported accumulation of DNA damage caused by RBMX loss of function ([@bib1]). Additionally, RBMX knockdown did not alter the predominantly cytoplasmic localization of *NORAD*, as indicated by subcellular fractionation experiments ([Figure 6B](#fig6){ref-type="fig"}). We conclude that RBMX is not an essential co-factor for *NORAD* expression or localization.

![RBMX is not required for *NORAD* expression or localization.\
(**A**) qRT-PCR analysis of *RBMX* and *NORAD* transcript levels in HCT116 CRISPRi cells after introduction of the indicated lentivirally-expressed sgRNA with or without doxorubicin treatment (1 μM for 24 hr). Quantification relative to *GAPDH*. n = 3 technical replicates. (**B**) Subcellular fractionation and qRT-PCR of *NORAD*, *GAPDH* (cytoplasmic control), or *NEAT1* (nuclear control) following introduction of control or *RBMX*-targeting sgRNAs. n = 3 biological replicates each with three technical replicates.](elife-48625-fig6){#fig6}

In sum, these results establish the essential role of PUM binding for the regulation of genomic stability by *NORAD*. A systematic examination of the subcellular localization of this lncRNA unequivocally established its predominantly cytoplasmic localization under baseline conditions as well as after treatment with DNA-damaging agents. Moreover, genetic complementation experiments demonstrated that PUM binding is essential, whereas RBMX interaction is dispensable, for the genome maintenance function of *NORAD*. These results further define and clarify the *NORAD* molecular mechanism of action and direct future investigation towards elucidation of the regulation and physiologic roles of the *NORAD*:PUM axis.

Materials and methods {#s3}
=====================

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                Designation                                   Source or reference                                                                                     Identifiers                                                                                                                                                Additional\
  (species) or resource                                                                                                                                                                                                                                                                                                                         information
  ---------------------------- --------------------------------------------- ------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------
  Gene (*Homo sapiens*)        *NORAD* (*LINC00657*)                         NA                                                                                                      Ensembl:ENSG00000260032                                                                                                                                    

  Cell line (*Homo sapiens*)   HCT116                                        ATCC                                                                                                    CCL-247, RRID:[CVCL_0291](https://scicrunch.org/resolver/CVCL_0291)                                                                                        

  Cell line (*Homo sapiens*)   *NORAD^-/-^* HCT116                           [@bib4]                                                                                                                                                                                                                                                            

  Cell line (*Homo sapiens*)   HCT116 CRISPRi                                this paper; see Materials and methods section Cell culture and generation of HCT116 CRISPRi cell line                                                                                                                                                              

  Antibody                     Anti-PUM1 (polyclonal rabbit)                 Santa Cruz                                                                                              sc-135049, RRID:[AB_10610604](https://scicrunch.org/resolver/AB_10610604)                                                                                  RIP

  Antibody                     Anti-PUM2 (polyclonal goat)                   Santa Cruz                                                                                              sc-31535, RRID:[AB_654939](https://scicrunch.org/resolver/AB_654939)                                                                                       RIP

  Antibody                     Anti-RBMX (monoclonal rabbit)                 Cell Signaling                                                                                          \#14794, RRID:[AB_2798614](https://scicrunch.org/resolver/AB_2798614)                                                                                      RIP,\
                                                                                                                                                                                                                                                                                                                                                WB (1:1000)

  Antibody                     Anti-PUM2 (monoclonal rabbit)                 Abcam                                                                                                   ab92390, RRID:[AB_10563318](https://scicrunch.org/resolver/AB_10563318)                                                                                    WB (1:1000)

  Antibody                     Anti-PUM1 (monoclonal rabbit)                 Abcam                                                                                                   ab92545, RRID:[AB_10563695](https://scicrunch.org/resolver/AB_10563695)                                                                                    WB (1:1000)

  Antibody                     Anti-GAPDH (monoclonal rabbit)                Cell Signaling                                                                                          \#2118, RRID:[AB_561053](https://scicrunch.org/resolver/AB_561053)                                                                                         WB (1:5000)

  Antibody                     Anti-phospho-histone H2A.X (Ser139)           Cell Signaling                                                                                          \#2577, RRID:[AB_2118010](https://scicrunch.org/resolver/AB_2118010)                                                                                       IF (1:500),\
                                                                                                                                                                                                                                                                                                                                                WB (1:1000)

  Antibody                     IRDye 800CW anti-rabbit (donkey)              Licor                                                                                                   925--32213, RRID:[AB_2715510](https://scicrunch.org/resolver/AB_2715510)                                                                                   WB (1:10000)

  Antibody                     Anti-Digoxigenin (monoclonal mouse)           Roche                                                                                                   11333062910, RRID:[AB_514495](https://scicrunch.org/resolver/AB_514495)                                                                                    RNA FISH

  Antibody                     Anti-Mouse IgG, Cy3 (polyclonal goat)         EMD Millipore                                                                                           AP124C                                                                                                                                                     RNA FISH

  Recombinant DNA reagent      *AAVS1/PPP1R12C* targeting vector             Addgene                                                                                                 \#22072, RRID:[Addgene_22072](https://scicrunch.org/resolver/Addgene_22072)                                                                                

  Recombinant DNA reagent      hAAVS1 1L TALEN; hAAVS1 1R TALEN              Addgene                                                                                                 \#35431, RRID:[Addgene_35431](https://scicrunch.org/resolver/Addgene_35431); \#35432, RRID:[Addgene_35432](https://scicrunch.org/resolver/Addgene_35432)   

  Recombinant DNA reagent      pU6-sgRNA EF1a-PuroR-T2A-BFP                  Addgene                                                                                                 \#60955, RRID:[Addgene_60955](https://scicrunch.org/resolver/Addgene_60955)                                                                                CRISPRi-mediated knockdown

  Sequence-based reagent       Chromosome enumeration Probe Chr. 7 (green)   Empire Genomics                                                                                         CHR07-10-GR                                                                                                                                                DNA FISH

  Sequence-based reagent       Chromosome enumeration Probe Chr. 20 (red)    Empire Genomics                                                                                         CHR20-10-RE                                                                                                                                                DNA FISH

  Software, algorithm          Prism 7                                       GraphPad Software                                                                                                                                                                                                                                                  

  Software, algorithm          Proteome Discoverer                           Thermo Fisher                                                                                                                                                                                                                                                      

  Software, algorithm          Limma package for R                           [@bib10]                                                                                                                                                                                                                                                           
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Cell culture and generation of HCT116 CRISPRi cell line {#s3-1}
-------------------------------------------------------

HCT116 cells (ATCC) were cultured in McCoy's 5a media (Thermo Fisher Scientific) supplemented with 10% FBS (Gibco, Sigma-Aldrich) and 1X AA (Gibco). The cell line was authenticated by ATCC using short tandem repeat (STR) analysis in November 2017. All cell lines were confirmed to be free of mycoplasma contamination. HCT116 *NORAD*^--/--^ cells were generated previously ([@bib4]).

To generate the HCT116 CRISPRi cell line, lentivirus expressing dCas9/BFP/KRAB was produced by first seeding 6 × 10^5^ HEK293T cells per well in a six-well plate. The following day, cells were transfected with 1.4 μg of pHR-SFFV-dCas9-BFP-KRAB (Addgene plasmid \#46911), 0.84 μg of psPAX2 (Addgene plasmid \#12260), 0.56 μg of pMD2.G (Addgene plasmid \#12259), 8.4 μl of FuGENE HD (Promega), and 165 μl Opti-MEM (Thermo Fisher) according to the manufacturer's instructions. Medium was changed the next day. Two days after transfection, medium was collected and passed through a 0.45 μm SFCA sterile filter. Recipient HCT116 cells were transduced overnight using medium supplemented with 8 μg/ml polybrene (EMD Millipore). Cells expressing BFP were enriched by FACS and single-cell clonal lines were derived.

RNA Fluorescent in situ hybridization (RNA FISH) {#s3-2}
------------------------------------------------

RNA FISH was performed as described previously ([@bib6]) with the following modifications. DIG-labeled RNA probes for human *NORAD* were synthesized by in vitro transcription using a DIG-labeling mix (Roche). Primers used for amplification of the DNA template for each probe are provided in [Supplementary file 1](#supp1){ref-type="supplementary-material"}. 2 × 10^5^ cells were grown on poly-L-lysine coated coverslips for 24 to 36 hr. For RNA FISH experiments with DNA damage treatment, cells were grown for 24 hr and treated with either 1 μM doxorubicin or 200 nM camptothecin for an additional 12 hr. Samples were rinsed twice in phosphate buffered saline (PBS), fixed in 4% paraformaldehyde for 10 min, washed again in PBS, and permeabilized in 0.5% Triton X-100 for 10 min. Samples were then washed twice with PBS and rinsed with DEPC-treated water prior to incubation in prehybridization buffer (50% formamide, 2X SSC, 1X Denhardt's solution, 10 mM EDTA, 0.1 mg/ml yeast tRNA, 0.01% Tween-20) for 1 hr. 10 ng/μl DIG-labeled RNA probe was diluted in hybridization buffer (prehybridization buffer with 5% dextran sulfate) and used for hybridization at 55°C for 16 to 20 hr. Following hybridization, samples were washed, treated with RNase A, and blocked using Blocking Reagent (Roche). DIG-labeled probes were detected using mouse monoclonal anti-DIG primary antibody (Roche; 1:100 dilution) and a Cy3-labeled goat anti-mouse IgG secondary antibody (Roche; 1:100 dilution). Immunofluorescence and western blot analysis of the DNA damage marker γ-H2AX was performed using anti-γ-H2AX (Ser139) antibody (2577, Cell Signaling). Samples were mounted using SlowFade Diamond Antifade with DAPI mounting media (Invitrogen) and imaging was performed using a Zeiss LSM700 confocal microscope. ImageJ was used for further image analysis.

Subcellular fractionation {#s3-3}
-------------------------

Cells were seeded in triplicate and 1 × 10^6^ cells were collected for subcellular fractionation, which was performed as previously described ([@bib3]; [@bib4]). Briefly, cell pellets were lysed in RLN1 buffer (50 mM Tris-HCl pH 8.0, 140 mM NaCl, 1.5 mM MgCl~2~, 0.5% NP-40, RNAse inhibitor) on ice for 5 min and centrifuged at 500g × 2 min. The supernatant containing the cytoplasmic fraction was separated from the pelleted nuclear fraction. RNA was then isolated from both fractions using the Qiagen RNeasy kit and equal cell equivalents of nuclear and cytoplasmic RNA were used in subsequent qRT-PCR reactions. All samples were tested for *NORAD* as well as *NEAT1* (nuclear control) and *GAPDH* (cytoplasmic control). The sum of the nuclear and cytoplasmic expression level of each transcript was set to 100%, and the percentage of each transcript localized to each compartment was determined. *NEAT1* and *GAPDH*, respectively, showed the expected nuclear and cytoplasmic localization in each experiment, confirming successful fractionation.

Reanalysis of *NORAD* RAP-MS data {#s3-4}
---------------------------------

The raw mass spectra files from iTRAQ-labeled *NORAD* and *RMRP* RAP-MS experiments ([@bib7]) were downloaded from MassIVE (<https://massive.ucsd.edu>) using the identifier: MSV000082561. Peptide identification and quantification was performed using Proteome Discoverer (Thermo Fisher) with three search engines combined (Sequest HT, Mascot, and MS Amanda). MS/MS spectra were searched against the human Uniprot database. Search parameters included: trypsin enzyme specificity with a maximum of 2 missed cleavages tolerated, False Discovery Rate (FDR) set to 0.01 at both peptide and protein level, ±10 ppm for precursor mass tolerance with a shorter window for fragment mass tolerance for the first search, and carbamidomethylation of cysteine modification and iTRAQ labels on N-termini and lysine residues as fixed modifications and oxidation of methionine and N-termini acetylation as variable modifications. All peptide and protein identifications had scores surpassing the combined search engine significance threshold for identification. Protein abundance was calculated as the intensity given from precursor quantification and was then normalized to the total peptide amount. To correct for total abundance differences between samples, protein and peptide abundance values in each sample were corrected by a constant factor such that the end total abundance was equivalent across all samples. Fold change was calculated as the log~2~ difference of average scaled protein abundance in *NORAD* samples and *RMRP* sample. For statistical analysis, we used the limma package ([@bib10]) in R (<https://www.r-project.org/>) to calculate the adjusted p-value using a moderated *t*-test and Benjamini Hochberg method to control the FDR.

RNA isolation and quantitative reverse transcription PCR (qRT-PCR) {#s3-5}
------------------------------------------------------------------

RNA was isolated from cells using the RNeasy Mini Kit (Qiagen), or, for RIP experiments, Trizol (Invitrogen), and treated with RNase-free DNase (Qiagen). RNA was reverse transcribed with PrimeScript RT-PCR mix (Clonetech), and Power SYBR Green PCR Master Mix (Applied Biosystems) was used for qPCR. Biological replicates represent independently grown and processed cells. Technical replicates represent multiple measurements of the same biological sample. Primer sequences are provided in [Supplementary file 1](#supp1){ref-type="supplementary-material"}.

Generation and *AAVS1* knock-in of *NORAD* constructs {#s3-6}
-----------------------------------------------------

Full-length wild-type *NORAD* was amplified from a modified pcDNA3.1 vector containing the *NORAD* cDNA ([@bib4]), along with an additional 115 base pairs downstream of the endogenous *NORAD* polyadenylation site. The PRE-mutant (PREmut) construct containing 18 PRE mutations (TGT to ACA) was synthesized by GENEWIZ. The 5′ deletion construct (∆1--898), 5′ fragment (nt 33--898), and ND4 were amplified from the full-length *NORAD* construct using primers provided in [Supplementary file 1](#supp1){ref-type="supplementary-material"}. Constructs were cloned into a *AAVS1/PPP1R12C* targeting vector (*AAVS1* hPGK-PuroR-pA donor, Addgene plasmid \#22072) modified by replacing the puromycin resistance gene with a hygromycin resistance gene and digested with KpnI and MfeI to remove the GFP cassette. These vectors, as well as a control GFP vector, were then inserted into the *AAVS1* locus of HCT116 CRISPRi cells using a previously described TALEN pair targeting the *AAVS1/PPP1R12C* locus ([@bib9]) (hAAVS1 1L TALEN, Addgene plasmid \#35431; hAAVS1 1R TALEN, Addgene plasmid \#35432). Transfection of these plasmids was performed using FugeneHD (Promega) at a 1:1:8 ratio of L-TALEN:R-TALEN:Donor as previously described ([@bib4]). 48 hr after transfection, cells were selected with hygromycin (500 μg/ml) for at least 10 days prior to introducing sgRNAs for CRISPRi-mediated knockdown.

CRISPRi-mediated knockdown {#s3-7}
--------------------------

Single guide RNAs (sgRNAs) targeting a sequence upstream of the endogenous *NORAD* transcription start site or targeting RBMX were cloned into a pU6-sgRNA EF1a-PuroR-T2A-BFP vector (Addgene plasmid \#60955). sgRNA sequences are provided in [Supplementary file 1](#supp1){ref-type="supplementary-material"}. pU6-sgRNA vectors were then packaged into lentivirus by transfecting HEK293T cells using a 4:2:1 ratio of pU6-sgRNA:psPAX2:pMD2.G with FuGENE HD. Medium was changed the next day. Media containing the virus was collected and filtered at 48 hr and 72 hr after transfection. Virus was then diluted 1:3 with fresh media and used to transduce HCT116 CRISPRi cell lines overnight in a final polybrene concentration of 8 μg/ml. 48 hr after transduction, selection with 1 μg/ml puromycin was initiated. For HCT116 CRISPRi cells with *AAVS1/NORAD* construct insertion and sgRNA expression, cells were grown in 1 μg/ml puromycin and 500 μg/ml hygromycin.

UV crosslinking and RNA immunoprecipitation (RIP) {#s3-8}
-------------------------------------------------

PUM1, PUM2, and RBMX RIP experiments were performed in HCT116 CRISPRi cells stably expressing *AAVS1/NORAD* constructs and depleted of endogenous *NORAD* with CRISPRi as described above. 20 × 10^6^ cells were washed in cold PBS and UV crosslinked on ice in a Spectrolinker XL-1500 (Spectronics) at 254 nm (400 mJ/cm^2^). Cells were then scraped, centrifuged, snap-frozen in liquid nitrogen, and stored at −80°C. RIP was performed following a modified eCLIP protocol ([@bib13]) as follows: Cells were lysed in 1 mL cold iCLIP lysis buffer (50 mM Tris-HCl, 100 mM NaCl, 1% NP-40, 0.1% SDS, 0.5% sodium deoxycholate, 1:200 Protease Inhibitor Cocktail III, RNAse inhibitor) for 25 min on ice. Lysed cells were then centrifuged at 14,000 g for 15 min at 4°C and the supernatant was added to pre-washed and antibody-coupled Protein G Dynabeads (Invitrogen). For each RIP, 5 μg of antibody (anti-PUM1, Santa Cruz sc-135049; anti-PUM2, Santa Cruz sc-31535; anti-RBMX, Cell Signaling \#14794; Goat IgG control, Santa Cruz sc-2028; Rabbit IgG control Cell Signaling \#2729) was coupled to 3.75 mg of beads at room temperature for 45 min, after which unbound antibody was removed. Sample and beads were incubated at 4°C overnight. The next day, beads were washed three times with 900 μL cold High Salt Wash Buffer \#1 (50mM Tris-HCl, 1M NaCl, 1 mM EDTA, 1% NP-40, 0.1% SDS, 0.5% sodium deoxycholate) and three times with 500 μL Wash Buffer \#2 (20mM Tris-HCl, 10 mM MgCl~2~, 0.2% Tween-20). Beads were then resuspended in 100 μL Wash Buffer \#2, and 70 μL was used for RNA extraction and the remainder for western blotting. Proteins were extracted by incubation in Laemmli buffer for 10 min at 70°C. Antibodies used for western blotting were anti-PUM1 (ab92545, Abcam), anti-PUM2 (ab92390, Abcam), and anti-RBMX (14794, Cell Signaling).

DNA fluorescence in situ hybridization (DNA FISH) {#s3-9}
-------------------------------------------------

Aneuploidy in *NORAD* construct rescue experiments was assessed 18 to 21 days after knockdown of endogenous *NORAD*. DNA FISH was performed as described previously ([@bib3]; [@bib4]). Chromosome enumeration probes for chromosome 7 (CHR7-10-GR) and chromosome 20 (CHR20-10-RE) were purchased from Empire Genomics. Cells were trypsinized, washed in PBS, and incubated in hypotonic 0.4% KCl solution for 5 min at room temperature. Cells were then fixed in 3:1 methanol:glacial acetic acid and dropped onto slides. DNA FISH hybridizations were performed by the Veripath Cytogenetics laboratory at UT Southwestern. Slides were analyzed using an AxioObserver Z1 microscope (Zeiss). For each sample, 200 nuclei were counted and aneuploidy was defined as a chromosome count that differed from 2 n for at least one of the two tested chromosomes. Samples were prepared and counted in an experimenter-blinded manner. Two independent HCT116 CRISPRi cell lines stably expressing each *AAVS1* knock-in construct were generated, and each was independently tested for aneuploidy using this method.

Quantification of chromosome segregation defects {#s3-10}
------------------------------------------------

For anaphase nuclei imaging, cells were plated on poly-L-lysine coated coverslips and grown for 24 hr. Samples were then fixed with 4% PFA in PBS for 10 min at room temperature, carefully washed with PBS, rinsed with DEPC-treated water, and mounted using SlowFade Diamond Antifade with DAPI mounting media (Invitrogen). Slides were analyzed using an AxioObserver Z1 microscope. For each sample, 100 anaphase nuclei were imaged and assessed for the presence of chromosome segregation defects. Samples were counted in an experimenter-blinded manner.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"PUMILIO, but not RBMX, binding is required for regulation of genomic stability by noncoding RNA *NORAD*\" for consideration by *eLife*. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by a Reviewing Editor and James Manley as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Igor Ulitsky (Reviewer \#1); Philip Grote (Reviewer \#2).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

In the manuscript, Mendell and colleagues describe an advance in their study of *NORAD*, a mouse loss-of-function model of which was previously published in *eLife*. In the new manuscript, the authors focus on human cells, where they can reliably test the effects of loss-of-function of *NORAD* an genome stability by measuring fraction of HCT116 cells that become aneuploid, following loss of *NORAD* combined with expression of different rescue constructs. In this setting, the authors test different sequence variants and measure the fraction or aneuploid cells. This system allows the authors to compare the relative contribution of two groups of regions within *NORAD* -- the \~20 PUMILIO binding sites, and the region that binds RBMX. RBMX was recently shown to bind *NORAD* by Munschauer et al., which showed that this binding is important for proper replication fork progression, and it was suggested in that paper that this binding is important overall for the roles of *NORAD* in genome stability. The new results convincingly show that PUMILIO binding is important for the aneuploid cell% phenotype (evaluated by measuring two chromosomes with DNA FISH). The authors also convincingly show that *NORAD* is mostly cytoplasmic in unstressed and in DNA-damaged cells, and that in contrast to the previous analysis by Muschauer et al., and consistently with all previous RIP and CLIP data, *NORAD* binds PUM1 and PUM2 PUMILIO proteins.

The topic of *NORAD* function and modes of action is of high interest, and the relative importance of the binding to PUMILIO in the cytoplasm and to RBMX in the nucleus for genome stability, as well as localization of *NORAD*, are a matter of controversy following the conflicting papers. The experiments are generally performed to a high standard and analyzed appropriately. The comments below mainly refer to the way the results are presented in context of prior work from the authors and from Munschauer et al., and are intended to provide a better distinction within the manuscript between the new results and discussion about the results of others.

Essential revisions:

The readout of genome integrity described by Munschauer et al. (% chromosome segregation defects) is not identical to the one described in this submission (and by Lee et al.: \"% aneuploid cells\") and so formally cannot invalidate Munschauer et al.\'s conclusions. Please comment on the possibility that, even with all the new results, *NORAD* has a dual function: as a modulator of PUMILIO factors and as an \"assembler\" of the NARC1 complex. For a more definitive result, the same phenotypic assays as described in the Munschauer paper would be required. Ideally this should be done, but if the same assay and same readout are not possible then statements (in the Title and Abstract and elsewhere) regarding RBMX binding not being important for genome stability would need to be toned down.

Additional comments:

• The Abstract mentions that much of the prior work published in *eLife* was in mouse, but should also clarify that the new results are mostly in human cells.

• Abstract. What is meant by the data providing \"a foundation for further investigation of this pathway\"? If not specific then this statement should be removed.

• Introduction section: The first sentence on lncRNAs is too generic and is not true for the majority of lncRNAs -- remove/edit.

• \"*NORAD* ... capacity to bind a large fraction of PUM1/2 within the cell\". Is there evidence that more than a few percent of PUM1/2 molecules per cell are bound at any time? Justify. What value is this large fraction?

• \"definitively demonstrated that this lncRNA localizes predominantly to the cytoplasm and does not traffic to the nucleus upon induction of DNA damage\". The authors do not exclude that some nuclear relocalization does happen. So this sentence (and others, Results paragraph four e.g.) should be toned down.

• Results section paragraph three: The authors should show that these conditions indeed lead to DNA damage.

• Results section: \"We conclude that the disparate localization pattern observed using a commercially available RNA FISH probe set (Munschauer et al., 2018) most likely represented a non-specific signal.\" Speculation, such as this, has a better fit to the Discussion section and here other possibilities should be discussed as well (e.g., differences in the HCT116 clones used in the different labs or differential accessibility of different probe sets to *NORAD* RNPs in the nucleus and in the cytoplasm).

• Results section: \"Since these RAP-MS experiments utilized pulse labeling with 4-thiouridine to crosslink *NORAD* to protein interactors, a bias towards detection of proteins that bind to newly synthesized *NORAD* would be expected, likely explaining the enrichment of nuclear interactors observed.\" This is also speculation and should be moved to the Discussion.

• Subsection "Binding of PUMILIO, but not RBMX, to *NORAD* is necessary for genome stability": It should be mentioned whether the 5\' region the authors use contains any PUMILIO binding sites

• In the same section: What happens to *NORAD* levels in the edited cells (with the extra *NORAD* variants in the AAVS locus) before CRISPRi? Are *NORAD* levels roughly double? This should be mentioned, as these transiently increased levels may affect the phenotype in cells after CRISPRi.

• Subsection "RBMX is not required for *NORAD* expression or localization": Speculation regarding how RBMX affects *NORAD* levels also should be placed in the Discussion.

• Can the authors please elaborate why the *NORAD*:RBMX study finds PUM only ranking 185th in the RAP-IP experiment and below the significant threshold? Why does applying the strategy with three search engines make this difference?

• There are no biological replicates in Figure 2D; why has Figure 2C biological replicates and not Figure 2D? Also, please provide statistics if the burst of *NORAD* in Figure 2C at 12h is significant.

• Please provide for the 2 independent clones in Figure 4C the analysis as in Figure 3B; does the degree of overexpression differ between the clones?

• Results paragraph one; perhaps \"Importantly, a single cell line (human colon cancer cell line HCT116) was used in both of these studies\"?

• Results paragraph four -- insert \"predominantly\": \"*NORAD* is a predominantly cytoplasmic RNA in HCT116 cells\"

• Subsection "PUM1, PUM2, and RBMX are components of the *NORAD* interactome": Please confirm whether the RAP-MS experiments used HCT116 cells also.

• Subsection "Binding of PUMILIO, but not RBMX, to *NORAD* is necessary for genome stability" paragraph three: *NORAD* \"interaction with RBMX was abolished\". Is this correct?

• Figure 4C Explain horizontal dotted line and add significance estimates for the different comparisons.

• Figure 4---figure supplement 1. Provide full legend that explains why there are 2 bands in the anti-PUM1 WB and try to improve on the anti-PUM2 WB.

• Subsection "Generation and AAVS1 knock-in of *NORAD* constructs": typo \"and ND4 and were amplified\"

10.7554/eLife.48625.018

Author response

> Essential revisions:
>
> The readout of genome integrity described by Munschauer et al. (% chromosome segregation defects) is not identical to the one described in this submission (and by Lee et al.: \"% aneuploid cells\") and so formally cannot invalidate Munschauer et al.\'s conclusions. Please comment on the possibility that, even with all the new results, NORAD has a dual function: as a modulator of PUMILIO factors and as an \"assembler\" of the NARC1 complex. For a more definitive result, the same phenotypic assays as described in the Munschauer paper would be required. Ideally this should be done, but if the same assay and same readout are not possible then statements (in the Title and Abstract and elsewhere) regarding RBMX binding not being important for genome stability would need to be toned down.

We have now performed the identical assay to that performed by Munschauer et al. (quantification of the frequency of chromosome segregation defects), which further demonstrates that RBMX binding is not essential for maintenance of genomic stability by *NORAD*. These new data have been added to Figure 5 of the revised manuscript. Similar to what we reported previously (Lee et al., 2016), and later confirmed by Munschauer et al., *NORAD* knockdown resulted in an increase in the percentage of anaphase cells that display defective chromosome segregation. Expression of full-length *NORAD*, or *NORAD* lacking the RBMX binding site, rescued this phenotype whereas mutation of the PUMILIO binding sites fully abrogated *NORAD* function in this assay.

It is worth noting that we initially chose the DNA FISH assay for the present study because it is a more sensitive readout of genome instability. DNA FISH reports the cumulative effect of chromosome segregation defects over many cell divisions whereas the analysis of mitoses provides a more limited snapshot of the defects present at a single time-point. Nevertheless, we appreciate the reviewers' suggestion to perform both assays, which have yielded essentially identical results, thereby providing an even more definitive demonstration that PUMILIO binding is essential, whereas RBMX binding is dispensable, for genome maintenance by *NORAD*.

The reviewers have also requested that we comment on the possibility that "*NORAD* has a dual function: as a modulator of PUMILIO factors and as an \"assembler\" of the NARC1 complex". First, our data establish that assembly of the NARC1 complex is neither necessary nor sufficient for the genome maintenance function of *NORAD*. Since deletion of the RBMX binding site does not impair *NORAD* function, assembly of NARC1 is not necessary for genome stability. Moreover, the PUMILIO binding site mutant, which retains the ability to interact with RBMX, behaves as a null in genome stability assays, thus demonstrating that assembly of NARC1 is not sufficient for genome maintenance. In light of these observations, the proposed ability of *NORAD* to assemble the NARC1 complex is not relevant to *NORAD*'s genome maintenance function and therefore we chose not to investigate it deeply in this study. Nevertheless, we have performed a limited number of experiments to examine whether *NORAD* is indeed necessary for the assembly of NARC1, as determined by assessing the interaction of RBMX with TOP1 (the readout of NARC1 assembly described in Munschauer et al.). As shown below, in co-immunoprecipitation assays in *NORAD* wild-type and knockout cells performed using epitope-tagged RBMX (using the conditions described in Munschauer et al.), we detect no difference in RBMX:TOP1 interaction in the absence of *NORAD*. We would prefer not to add these data to our manuscript, however, because this experiment is tangential to our main conclusion, which is that NARC1, whether or not it forms, has no role in the genome maintenance function of *NORAD*. Clearly, substantial additional work would be necessary to establish the conditions, if any, under which *NORAD* stimulates assembly of this complex and its functional relevance.

![Co-immunoprecipitation of RBMX and TOP1 in *NORAD*wild-type and knockout cells.\
FLAG-tagged RBMX was stably expressed in HCT116 cells and immunoprecipitated using identical conditions as that described in Munschauer et al., 2018.](elife-48625-resp-fig1){#respfig1}

> Additional comments:
>
> • The Abstract mentions that much of the prior work published in eLife was in mouse, but should also clarify that the new results are mostly in human cells.

We have edited the Abstract to indicate that the present study utilized human cells.

> • Abstract. What is meant by the data providing \"a foundation for further investigation of this pathway\"? If not specific then this statement should be removed.

By clarifying the mechanism of action of *NORAD*, the data reported in this study provide an "important foundation for further mechanistic dissection of the *NORAD*-PUMILIO axis in genome maintenance", as it is now phrased in the Abstract.

> • Introduction section: The first sentence on lncRNAs is too generic and is not true for the majority of lncRNAs -- remove/edit.

The first sentence of the Introduction has been edited to: "Long noncoding RNAs (lncRNAs) have emerged as regulators of diverse biological processes." This no longer infers that this is true for the majority of lncRNAs, simply that some act as *bona fide* regulators.

> • \"NORAD ... capacity to bind a large fraction of PUM1/2 within the cell\". Is there evidence that more than a few percent of PUM1/2 molecules per cell are bound at any time? Justify. What value is this large fraction?

Given our previous measurements of *NORAD* copy number per cell, the number of PUM binding sites per *NORAD* molecule, and the number of PUM1/PUM2 proteins per cell (Lee et al., 2016), it is accurate to state that *NORAD* "has the capacity to bind a large fraction of PUM1/2 within the cell." As described in that previous publication, there are sufficient PUM binding sites provided by *NORAD* to bind up to 100% of the cellular PUM1/PUM2 pool. However, we agree that it is not clear what fraction of PUM1/2 is actually bound to *NORAD* at any given time, so we have rephrased the sentence to acknowledge that "...it is not yet known whether *NORAD* limits PUM activity through a simple sequestration model or whether additional mechanisms contribute to PUM inhibition."

> • \"definitively demonstrated that this lncRNA localizes predominantly to the cytoplasm and does not traffic to the nucleus upon induction of DNA damage\". The authors do not exclude that some nuclear relocalization does happen. So this sentence (and others, Results paragraph four e.g.) should be toned down.

We have rephrased the sentence in the Introduction to: "...this lncRNA localizes predominantly to the cytoplasm and does not detectably redistribute to the nucleus upon induction of DNA damage." Given that the localization pattern of *NORAD* is predominantly cytoplasmic with or without DNA damage, without an increase in nuclear signal under any tested conditions, we believe that this is an accurate description of the results.

Similarly, we revised the relevant sentence in the Results and Discussion section to read: "These comprehensive RNA FISH and subcellular fractionation experiments provide definitive evidence that *NORAD* is a predominantly cytoplasmic RNA in HCT116 cells and does not detectably redistribute to the nucleus upon DNA damage.

> • Results section paragraph three: The authors should show that these conditions indeed lead to DNA damage.

We have added γ-H2AX immunofluorescence and western blot data to Figure 2---figure supplement 1 of the revised manuscript, which confirms that doxorubicin and camptothecin treatment lead to DNA damage.

> • Results section: \"We conclude that the disparate localization pattern observed using a commercially available RNA FISH probe set (Munschauer et al., 2018) most likely represented a non-specific signal.\" Speculation, such as this, has a better fit to the Discussion section and here other possibilities should be discussed as well (e.g., differences in the HCT116 clones used in the different labs or differential accessibility of different probe sets to NORAD RNPs in the nucleus and in the cytoplasm).

*eLife* allows a versatile format for Research Advance articles and we have chosen to write our manuscript with a combined Results and Discussion section. We believe that this is the most effective means to communicate the results and conclusions of this study. In light of our use of this format, reasonable speculation to provide plausible explanations for disparate results is appropriately located immediately following the presentation of each main experiment. We have edited the text as follows to make it clear that the specific sentence to which the reviewer refers is speculation:

"We speculate that the disparate localization pattern observed using a commercially-available RNA FISH probe set (Munschauer et al., 2018) most likely represented a non-specific signal."

We do not believe that differences in HCT116 clones provides a likely explanation for the disparate localization patterns observed. The HCT116 cells used in our current and previous localization studies were purchased from ATCC and do not represent a laboratory-specific clone. We and others have reported an identical, cytoplasmic localization pattern in U2OS cells and MEFs (Tichon et al., 2016; Kopp et al., 2019). Moreover, fractionation studies in a large panel of cell lines, including the experiments reported here, have similarly demonstrated cytoplasmic localization of *NORAD* with or without DNA damage (Lee et al., 2016; Tichon et al., 2016; Kopp et al., 2019).

Similarly, we do not believe that differential accessibility of different probe sets to *NORAD* RNPs in the nucleus or cytoplasm provides a plausible explanation for the disparate localization patterns observed. We and others have previously reported predominantly cytoplasmic localization of *NORAD* using RNA FISH with tiled oligonucleotide probe sets (Lee et al.,2016; Tichon et al.,2016), which is the same type of probe used by Munschauer et al. Our new data generated using in vitro transcribed probes spanning the entire length of *NORAD* further support cytoplasmic localization. Equally importantly, the extensive subcellular fractionation studies reported here and elsewhere (Lee et al., 2016; Tichon et al., 2016; Kopp et al., 2019) further demonstrate cytoplasmic localization of *NORAD* with or without DNA damage, providing a completely independent experimental approach to support this conclusion.

> • Results section: \"Since these RAP-MS experiments utilized pulse labeling with 4-thiouridine to crosslink NORAD to protein interactors, a bias towards detection of proteins that bind to newly synthesized NORAD would be expected, likely explaining the enrichment of nuclear interactors observed.\" This is also speculation and should be moved to the Discussion.

As described above, this manuscript is formatted with a combined Results and Discussion section. As such, reasonable speculation and data interpretation follows the presentation of each main experiment. Regarding the specific sentence to which the reviewer refers, we have further edited the text to make it clear that we are speculating here:

"Since these RAP-MS experiments utilized pulse labeling with 4-thiouridine to crosslink *NORAD* to protein interactors, a bias towards detection of proteins that bind to newly synthesized *NORAD* would be expected, potentially explaining the enrichment of nuclear interactors observed."

> • Subsection "Binding of PUMILIO, but not RBMX, to NORAD is necessary for genome stability": It should be mentioned whether the 5\' region the authors use contains any PUMILIO binding sites

This fragment does contain one PRE and we have modified the text accordingly:

"An RBMX binding site fragment, representing the 5\' end of *NORAD* (nt 33-898), which also harbors one PRE, was also generated (5\' fragment)."

A PRE in this segment of *NORAD* is also apparent in Figure 3A.

> • In the same section: What happens to NORAD levels in the edited cells (with the extra NORAD variants in the AAVS locus) before CRISPRi? Are NORAD levels roughly double? This should be mentioned, as these transiently increased levels may affect the phenotype in cells after CRISPRi.

These data are provided in Figure 3C and we now explicitly describe these results in the text as follows:

"As expected, in cells infected with a non-targeting control sgRNA (sgControl), increased total levels of *NORAD* were observed upon expression of *NORAD* rescue constructs in *trans* (\~1.5-6 fold overexpression, depending on the construct) (Figure 3C). Upon silencing of the endogenous *NORAD* locus, however, near physiologic expression levels for all constructs were achieved, with the exception of the 5\' fragment which exhibited \~3-fold overexpression, perhaps indicating increased stability of this transcript segment when expressed in isolation."

Moreover, we showed that increased *NORAD* expression in control cells does not result in genomic instability. These data were included in our original manuscript and are now shown in Figure 5B of the current version. In the text, we describe these results as follows:

"Importantly, no significant increase in aneuploidy was observed in any of the *NORAD* rescue populations after infection with non-target sgRNA (sgControl), indicating that overexpression of the *NORAD* constructs in *trans* did not trigger genomic instability."

> • Subsection "RBMX is not required for NORAD expression or localization": Speculation regarding how RBMX affects NORAD levels also should be placed in the Discussion.

As described above, this manuscript is formatted with a combined Results and Discussion section. As such, reasonable speculation and interpretation follows the presentation of each main experiment.

> • Can the authors please elaborate why the NORAD:RBMX study finds PUM only ranking 185th in the RAP-IP experiment and below the significant threshold? Why does applying the strategy with three search engines make this difference?

Because the Munschauer et al. study analyzed the RAP-MS experiment using proprietary software that we do not have access to (Spectrum Mill v6.01 pre-release from Agilent Technologies), we are unable to reproduce their analysis and therefore we cannot state definitively why PUM proteins were not more highly ranked in their reported results. However, several aspects of their analysis are notable and may have contributed to their findings. First, we detect two isoforms for both PUM1 and PUM2. We do not know which isoform they refer to as PUM2 (ranked 185 in their analysis) and they do not comment on the PUM1 ranking (which is significantly higher than PUM2 in our analysis). Second, their ranking is based on fold increase in *NORAD* signal compared to signal observed in RMRP pull-down. We do not think RMRP pull-down is the ideal control since different proteins will exhibit different levels of binding to RMRP which may or may not represent background. Instead, we believe that *NORAD* knockout would have been a better control. Regardless, they chose to set a log~2~ fold-increase of 1.6 (*NORAD*/RMRP pull-down), with p \< 0.05, as their arbitrary significance threshold. Notably, we observe PUM1 immediately below the enrichment cut-off of log~2~ 1.6, with a more significant p-value than RBMX (see Figure 3---figure supplement 1). Nevertheless, we would prefer not to comment further on their analysis since the data are clear that i) PUM1 and PUM2 are detectable interactors by RAP-MS and ii) these interactions have been confirmed in multiple independent CLIP datasets from human and mouse cells.

> • There are no biological replicates in Figure 2D; why has Figure 2C biological replicates and not Figure 2D? Also, please provide statistics if the burst of NORAD in Figure 2C at 12h is significant.

We now provide biological triplicates for the experiments in Figure 2D and Figure 2---figure supplement 1D (subcellular fractionation after treatment with doxorubicin/camptothecin plus actinomycin D). In addition, we provide statistics in Figure 2C and Figure 2---figure supplement 1C, showing that the burst of *NORAD* expression after doxorubicin/camptothecin treatment is indeed statistically significant.

> • Please provide for the 2 independent clones in Figure 4C the analysis as in Figure 3B; does the degree of overexpression differ between the clones?

The expression levels of all *NORAD* constructs in both replicates is now provided in Figure 3C of the revised manuscript. Both clones exhibit very similar levels of expression of *NORAD* rescue constructs.

> • Results paragraph one; perhaps \"Importantly, a single cell line (human colon cancer cell line HCT116) was used in both of these studies\"?

We have edited this sentence as follows:

"Importantly, a single cell line (human colon cancer cell line HCT116) was used in both the previous (Lee et al., 2016) and more recent studies (Munschauer et al., 2018), arguing against a cell-type specific difference in *NORAD* trafficking as the cause of these discordant results."

> • Results paragraph four -- insert \"predominantly\": \"NORAD is a predominantly cytoplasmic RNA in HCT116 cells\"

Edited as suggested.

> • Subsection "PUM1, PUM2, and RBMX are components of the NORAD interactome": Please confirm whether the RAP-MS experiments used HCT116 cells also.

HCT116 cells were indeed used in the RAP-MS experiments and this is now indicated in the text.

> • Subsection "Binding of PUMILIO, but not RBMX, to NORAD is necessary for genome stability" paragraph three: NORAD \"interaction with RBMX was abolished\". Is this correct?

As shown in Figure 4A of the revised manuscript, the 5\' deletion and ND4 fragments of *NORAD* exhibit minimal enrichment after RBMX pull-down relative to IgG (\~1.0-1.3 fold enrichment). This magnitude of enrichment is indistinguishable from experimental noise. To more accurately describe these results, we revised the text to state that "interaction with RBMX was not detectable above background."

> • Figure 4C Explain horizontal dotted line and add significance estimates for the different comparisons.

The horizontal line indicates the highest level of aneuploidy observed in the sgControl samples. Because this is a complex figure with many data points, we feel that inclusion of this line aids the reader in distinguishing samples with elevated aneuploidy from those without. We have added a similar line to the new Figure 5D (% chromosome segregation defects). Both lines are defined in the figure legend. In addition, significance estimates are provided for all genome stability assays (Figure 5B,D).

> • Figure 4---figure supplement 1. Provide full legend that explains why there are 2 bands in the anti-PUM1 WB and try to improve on the anti-PUM2 WB.

We have added a legend to Figure 4---figure supplement 1 that explains that PUM1 migrates as a doublet in HCT116 cells, possibly indicating post-translational modification or alternative splicing. We have confirmed that both bands represent PUM1 protein using siRNA knockdown experiments (not shown). We have replaced the PUM2 and RBMX blots in this figure with higher quality western blots.

> • Subsection "Generation and AAVS1 knock-in of NORAD constructs": typo \"and ND4 and were amplified\"

Thank you for highlighting this typo, which we have now corrected.
